The Transformation of the Pharmaceutical Industry Is Putting Pressure on Finland and Europe
Companies are becoming increasingly selective about where they launch new medicines and where they invest in research.
Mariann completed her Master of Science degree at the Department of Biosciences of the University of Helsinki in 2007, majoring in Physiology and minoring in Biochemistry. She finished her PhD in June 2016 with research concentrating on diabetes and the long-term complications related to the disease.
We want to warmly welcome Mariann to our growing team!

Companies are becoming increasingly selective about where they launch new medicines and where they invest in research.
Medaffcon’s Sales Lead Tomi "Tomppa" Vahevaara will retire on October 1st 2026. Tomppa leaves behind an exceptionally long career in the pharmaceutical industry spanning 45 years.
Medaffcon’s new Treatment Dynamics service provides insights into patient journeys, treatment progression, medication use and market dynamics through tailored patient-level real-world data analysis.